BioIntelliSense

Golden, CO All United States companies → — Founded 2019

Clinical AI Platform Wearables / RPM

Geriatrics Hospital Medicine Internal Medicine

Triage & ER/ICU AI Wearables & Remote Monitoring (RPM)

Series C — $319M

Website Claim this company

Products

BioIntelliSense BioCloud

BioIntelliSense, Inc.

Triage & ER/ICU AI

BioIntelliSense provides an FDA-cleared, medical-grade Data-as-a-Service (DaaS) platform with wearable biosensors (BioSticker, BioButton) for continuous vital sign monitoring and AI-powered analytics, delivering actionable clinical insights for proactive patient care in both in-facility and at-home settings.

Contact for pricing

See all 1 product →

About BioIntelliSense

BioIntelliSense is a leading healthcare AI company dedicated to transforming patient monitoring through its continuous health monitoring and clinical intelligence platform. The company offers a medical-grade Data-as-a-Service (DaaS) solution that seamlessly captures multi-parameter vital signs and physiological biometrics via an effortless patient experience. Their FDA-cleared wearable devices, such as the BioButton® and BioSticker™, are designed for continuous, passive monitoring of critical health indicators including heart rate, respiratory rate, skin temperature, activity levels, body position, and gait analysis. This comprehensive data collection aims to provide a more complete picture of a patient’s health status than intermittent measurements.

The BioIntelliSense ecosystem integrates these wearable sensors with BioHub® gateways, BioMobile™ applications, BioCloud™ data services, and the BioDashboard™ clinical intelligence system. This integrated platform leverages AI-driven analytics to identify statistically meaningful changes from baseline physiology and generate contextual notifications. For physicians, this translates into high-resolution patient trending and actionable insights, facilitating exception-based management and supporting early detection of clinical deterioration. The goal is to enable proactive clinical decision-making, streamline workflows, reduce hospital readmissions, and ultimately improve patient outcomes across various care settings, from acute in-hospital care to post-discharge and chronic remote care management.

By pioneering a new standard of scalable proactive monitoring, BioIntelliSense addresses critical needs in modern healthcare, including alleviating burdens on nursing staff and enhancing the effectiveness of virtual care programs. Their mission is to make physiological monitoring accessible to every patient, leveraging advanced technology to deliver better, safer, and more cost-effective care by moving from reactive to proactive health management.

Focus Areas

Continuous Health Monitoring Clinical Intelligence Remote Patient Monitoring (RPM) Medical-Grade Wearable Devices Data-as-a-Service (DaaS) Platform AI-driven Analytics Virtual Care In-Hospital Patient Monitoring At-Home Patient Monitoring

Business Intelligence

Key Investors	Chimera, 7wire Technology Partners, Mary Tolan of Chicago Pacific Founders, James Murren, Pendrell Corporation, Royal Philips, Fresenius Medical Care North America, TripleTree Holdings, UCHealth, CU Healthcare Innovation Fund, Confluent, Dexcom Ventures, TLG Capital Management
Partnerships	Medtronic, Hicuity Health, Renown Health, iRhythm, Philips, Houston Methodist, Medically Home
Acquisitions	AlertWatch
Technology	Data-as-a-Service (DaaS) platform, BioButton® multiparameter wearables, BioHub™ gateways (Wi-Fi, cellular, 5G), BioMobile™ downloadable applications, BioCloud™ data services, BioDashboard™ clinical intelligence system, AI-driven analytics, cloud-native (AWS), Rhapsody (for integration)
FDA Clearances	2 cleared products (estimated)

What Physicians Need to Know

Continuous Health Monitoring

BioIntelliSense offers continuous, multi-parameter vital sign and biometric measurements using FDA-cleared wearable devices like the BioButton and BioSticker. These devices passively collect up to 1,440 measurements per day, providing a high-resolution view of a patient's health both in facilities and at home.

Clinical Intelligence

The BioIntelliSense platform leverages AI-driven analytics and algorithmic-based notifications to provide clinical intelligence. The BioDashboard displays statistically meaningful changes from baseline physiology and contextual notifications, enabling early detection of patient deterioration and supporting proactive clinical decisions.

Remote Patient Monitoring (RPM)

Specializing in scalable RPM, BioIntelliSense's BioButton system facilitates seamless transitions of monitoring from in-hospital to home settings. Their solutions are designed to be RPM reimbursable, supporting post-acute care and chronic disease management.

Medical-Grade Wearable Devices

The core of their offering includes FDA-cleared medical-grade wearable devices such as the BioButton (available in disposable and rechargeable versions) and BioSticker. These discreet, comfortable sensors continuously capture over 20 physiological biometrics, including heart rate, respiratory rate, skin temperature, activity, body position, sleep, and gait analysis.

Data-as-a-Service (DaaS) Platform

BioIntelliSense provides a medical-grade Data-as-a-Service (DaaS) platform that seamlessly captures multi-parameter vital signs and physiological biometrics. This cloud-hosted service (BioCloud) ingests wearable data, provides clinical insights, personalized alerts, and exception-based triage.

AI-driven Analytics

The platform utilizes AI-driven analytics to detect adverse trends in vital signs, providing high-resolution patient trending and data-driven insights. This enables earlier detection of deterioration events, on average 14.8 hours prior to symptomatic changes.

Virtual Care

BioIntelliSense supports virtual care initiatives, including virtual rounding optimization and hospital-at-home programs. Their technology integrates with telehealth platforms to provide an end-to-end RPM suite, enhancing the delivery of remote medical-grade care.

In-Hospital Patient Monitoring

For in-hospital settings, the BioButton system automates continuous vital sign collection in non-critical care units, reducing the burden of manual spot checks. This leads to improved patient safety, streamlined workflows, and enhanced patient and nurse satisfaction.

At-Home Patient Monitoring

The BioButton system extends continuous monitoring to the home, offering a patient-friendly experience for post-discharge surveillance and chronic care management. Data is passively collected and transferred via mobile apps or cellular gateways to providers.

Physician Tip

For physicians, BioIntelliSense stands out by offering **earlier detection of patient deterioration** (averaging 14.8 hours in advance), which can significantly reduce unplanned ICU admissions, rapid response team activations, and overall length of hospital stay. The **automation of high-frequency vital sign collection** frees up nursing staff, allowing them to focus on patients who need care most, and contributes to reduced burnout. The **BioDashboard provides actionable, personalized insights and alerts** through an exception management approach, minimizing alert fatigue while ensuring critical changes are highlighted. The **scalable monitoring capabilities** seamlessly extend from in-hospital to home, supporting virtual care models, chronic disease management, and post-discharge care. Furthermore, the **RPM reimbursable nature** of their FDA-cleared devices offers clear financial benefits for practices. The discreet and effortless patient experience of the wearables also contributes to higher patient satisfaction.

BioIntelliSense's BioButton and BioDashboard System is a sophisticated cloud-based platform designed for **robust third-party and EMR system integration and data exchange capabilities**. They have demonstrated successful integration with Electronic Medical Record systems like Epic to streamline clinical workflows. The company also forms strategic partnerships with virtual care providers, such as Hicuity Health and VeeMed, to offer fully managed, end-to-end continuous patient monitoring services, addressing staffing and infrastructure challenges for health systems.

At a glance

Founded 2019

HQ Golden, CO · United States

Team size 102

CEO David Wang

Funding Series C — $319M

FDA clearances 2 (estimated)

Products 1

Visit site

Products by BioIntelliSense

1 product in the directory

BioIntelliSense BioCloud

BioIntelliSense, Inc.

Triage & ER/ICU AI

Contact for pricing

What the Web Says

BioIntelliSense offers continuous health monitoring and clinical intelligence solutions through wearable devices like the BioSticker and BioButton. These devices collect physiological data such as heart rate, respiratory rate, skin temperature, and activity levels for up to 30 days, aiming to provide early detection of patient deterioration and improve patient outcomes. The company's technology is designed to be user-friendly for patients and to streamline workflows for healthcare providers.

Overall: Positive

Strengths

Continuous and accurate monitoring of vital signs and physiological biometrics.
Early detection of patient deterioration, with notifications often preceding events.
Reduces the time nurses spend on manual vital sign collection, allowing for more patient interaction.
Can lead to a shorter average length of stay for patients in medical-surgical units.
Effortless patient experience with non-invasive, easy-to-wear devices.
HIPAA compliant and aligns with security standards.

Limitations

Concerns about data not being accurate have been raised.
Proper training is required for doctors, nurses, and IT staff to use the system effectively.
Some studies on the BioButton device for physical activity monitoring in children noted missing data due to discomfort or visibility.
The original BioButton was a single-use device, though a rechargeable version is now available.
Limited information available on employee reviews from major platforms like Glassdoor or Capterra, making it difficult to assess overall company culture or employer sentiment.

Based on reviews from: Health Technology Review - DoH, Zippia, Early Detection of 73% of Clinical Deterioration Events Using AWS with BioIntelliSense, Evidence - BioIntelliSense, Validation of the BioIntelliSense BioButtonu00ae device for physical activity monitoring in children and future application as a physical health outcome for critically Ill children - PMC, BioIntelliSense BioButtonu2122 Named Best New Monitoring Solution by MedTech Breakthrough Awards - PR Newswire, Tracking not just data, but individual symptoms, like vomiting: BioIntelliSense exits stealth with FDA-cleared wearable | Fierce Biotech, BioIntelliSense 2026 Company Profile: Valuation, Funding & Investors | PitchBook, BioIntellisense Careers and Employment | Indeed.com, BioIntelliSense debuts rechargeable version of its wearable vital sign tracker, How a wearable is optimizing patient monitoring at Houston Methodist - Becker's Hospital Review | Healthcare News & Analysis

Last updated: 2026-07-21

Videos

News, demos, and interviews about BioIntelliSense.

Loading videos...

Videos load interactively. If none appear, search YouTube for BioIntelliSense →

View all on YouTube

Press & Coverage

BioIntelliSense (via PR Newswire)

BioIntelliSense Announces Observational Study in Journal of Clinical Medicine

BioIntelliSense announced the publication of a peer-reviewed study in the Journal of Clinical Medicine, highlighting that continuous multiparameter vital sign monitoring with their BioButton device significantly improved patient outcomes in nearly 12,000 hospitalized patients. The study demonstrated a reduction in patient length of stay and early detection of clinical deterioration.

2025-11

BioIntelliSense (via PR Newswire)

BioIntelliSense Announces FDA Clearance of the BioButtonu00ae Multi-Patient Wearable and BioDashboardu2122

BioIntelliSense received FDA clearance for its rechargeable BioButtonu00ae Multi-Patient wearable and BioDashboardu2122 system, designed to scale hospital virtual care programs and automate vital sign collection. This expands their continuous monitoring solutions for inpatient and home-based care.

2024-10

Medical Device Network

FDA approval of BioIntelliSense's patient monitoring system signals major progress in remote patient monitoring market

BioIntelliSense's FDA approval for its BioButton Multi-Patient wearable and BioDashboard system is a significant advancement in the remote patient monitoring (RPM) market, which is projected to grow to $760 million by 2030. This solution automates vital sign collection and provides real-time data, bridging the gap between consumer health tracking and clinical demands.

2024-11

Business Wire

BioIntelliSense Announces Completion of Houston Methodist Inpatient Expansion of the BioButtonu00ae Continuous Patient Monitoring Solution

Houston Methodist has completed the inpatient expansion of BioIntelliSense's BioButtonu00ae continuous patient monitoring solution across all 2,653 non-ICU beds in its eight hospitals. This initiative aims to automate vital sign collection, improve patient safety, and enhance workflow efficiencies.

2024-04

Frontiers in Pediatrics (via PMC)

Validation of the BioIntelliSense BioButtonu00ae device for physical activity monitoring in children and future application as a physical health outcome for critically Ill children

A study published in Frontiers in Pediatrics validated the BioIntelliSense BioButtonu00ae device for accurately characterizing physical activity in children, suggesting its potential as an objective measure for physical health outcomes in critically ill children. The BioButton received FDA 510(k) clearance in December 2022 for pediatric research.

2025-04

BioIntelliSense

Solving for Telemetry Overuse in Patient Monitoring with BioIntelliSense

This article discusses the challenges of telemetry overuse in hospitals, including operational strain, patient safety risks, and financial impact, and positions BioIntelliSense's wearable technology as a solution to bridge the gap with smart, continuous monitoring.

2026-02

PR Newswire

BioIntelliSense Closes Oversubscribed $45M Series B Financing Round to Scale Its Data-as-a-Service and Clinical Intelligence Platform

BioIntelliSense closed an oversubscribed $45 million Series B financing round to support its growth and global expansion of medical-grade wearable devices and advanced data services for scalable remote care. This funding followed prior Series A rounds in 2019 and 2020.

2021-07

BioIntelliSense (via PR Newswire)

BioIntelliSense Acquires Alertwatch Clinical Intelligence Engine

BioIntelliSense acquired AlertWatchu00ae, an FDA-cleared patient monitoring solution that provides robust integration, data analysis, and an intuitive display of contextual patient data. This acquisition, coupled with a strategic partnership with Medtronic, aims to offer comprehensive continuous monitoring solutions.

2022-10

Frequently Asked Questions

What are BioIntelliSense's core products and how do they facilitate continuous health monitoring?

BioIntelliSense's core products include the FDA-cleared BioButton wearable devices (available in single-use and multi-patient rechargeable versions), BioHub gateways, BioMobile applications, and the BioDashboard clinical intelligence system, all supported by BioCloud data services. These medical-grade devices continuously capture multi-parameter vital signs and physiological biometrics up to 1,440 times per day, wirelessly transmitting data for comprehensive health monitoring.

How does BioIntelliSense's platform support both remote patient monitoring (RPM) and in-hospital patient monitoring?

The BioIntelliSense platform offers versatile solutions for both remote and in-hospital monitoring. For RPM, the BioButton devices enable continuous monitoring for post-discharge, chronic care, and virtual care at home, with data transmitted via mobile apps or cellular gateways. In hospitals, the BioButton Multi-Patient wearable is used in non-critical units, emergency departments, and specialty care areas, integrating with EMRs and utilizing Wi-Fi gateways for real-time insights.

What clinical intelligence and AI-driven analytics capabilities does BioIntelliSense offer to improve patient care?

BioIntelliSense leverages AI-driven analytics within its BioCloud platform and BioDashboard interface to provide high-resolution patient trending and algorithmic-based notifications. This clinical intelligence enables early detection of patient deterioration, with studies showing 73% of events detected early, and helps reduce manual vital sign collection by 50%, ultimately improving patient outcomes and operational efficiency.

How does BioIntelliSense ensure data security and regulatory compliance (e.g., HIPAA, FDA clearance) for its medical-grade devices and DaaS platform?

BioIntelliSense ensures regulatory compliance through FDA clearance for its BioButton and BioSticker devices, as well as the BioDashboard system, confirming their medical-grade status. The company's Data-as-a-Service (DaaS) platform and associated data services are designed to be HIPAA-compliant and adhere to strict privacy and security standards, with data transmitted securely.

What is the typical pricing model for BioIntelliSense's solutions, and what kind of support is provided to healthcare organizations?

BioIntelliSense offers cost-effective data services, aiming to be a fraction of the cost of traditional monitoring systems, with estimates around ~$10 per patient per day for continuous monitoring including system and clinician labor. They provide support for designing and implementing continuous monitoring programs, including assistance with rural health transformation initiatives and partnerships for fully managed monitoring services.

Can you describe BioIntelliSense's partnership ecosystem and its overall company stability in the healthcare AI market?

BioIntelliSense has established a robust partnership ecosystem, including strategic collaborations with Medtronic for exclusive U.S. distribution, Philips for RPM integration, and Hicuity Health for managed monitoring services. The company demonstrates stability and growth through continuous product innovation, frequent FDA clearances, and expanding partnerships with major healthcare systems like Houston Methodist and UC Davis Health, positioning itself as a leader in continuous health monitoring and clinical intelligence.

How do BioIntelliSense's wearable devices compare to other solutions in terms of patient comfort, data accuracy, and battery life?

BioIntelliSense's wearable devices, like the BioButton, are designed for patient comfort, being discreet, easy to apply, and capable of withstanding daily activities. They offer medical-grade data accuracy, capturing up to 1,440 vital sign measurements daily with high precision for heart and respiratory rates. Battery life varies by device, with the disposable BioButton offering up to 90 days, the rechargeable BioButton up to 30 days on a single charge, and in-facility versions typically lasting 14 days.

Related Companies

Suggest an Edit →